Canada Pension Plan Investment Board Purchases New Shares in Stryker Corporation $SYK

Posted by Geri Gentry on Aug 27th, 2026

Canada Pension Plan Investment Board acquired a new position in Stryker Corporation (NYSE:SYK – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 488,517 shares of the medical technology company’s stock, valued at approximately $153,805,000.

Several other institutional investors and hedge funds also recently made changes to their positions in SYK. Norges Bank purchased a new position in shares of Stryker in the fourth quarter valued at $1,822,272,000. Auto Owners Insurance Co grew its position in Stryker by 35,047.0% during the fourth quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock valued at $1,024,444,000 after acquiring an additional 2,906,448 shares during the last quarter. Legal & General Group Plc bought a new position in shares of Stryker during the second quarter valued at about $707,212,000. Flossbach Von Storch SE purchased a new position in shares of Stryker in the second quarter worth $464,506,000. Finally, Wellington Management Group LLP grew its position in shares of Stryker by 22.6% in the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock worth $2,282,192,000 after buying an additional 1,198,665 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Trading Down 0.2%

NYSE SYK opened at $330.08 on Thursday. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86. The company has a market capitalization of $126.61 billion, a PE ratio of 34.21, a P/E/G ratio of 2.11 and a beta of 0.76. The company has a fifty day moving average of $328.37 and a 200 day moving average of $331.72. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK – Get Free Report) last announced its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. During the same quarter last year, the firm posted $3.13 EPS. The business’s revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Research analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Insider Activity

In related news, insider Dylan Bram Crotty sold 441 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the completion of the transaction, the insider directly owned 6,102 shares in the company, valued at $2,005,178.22. This trade represents a 6.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Ronda E. Stryker sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the completion of the transaction, the director directly owned 2,251,375 shares of the company’s stock, valued at approximately $765,692,637.50. The trade was a 2.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 351,267 shares of company stock valued at $118,197,701. 4.60% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

SYK has been the subject of a number of recent research reports. Citizens Jmp lowered their price target on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a research report on Monday, August 3rd. Leerink Partners dropped their price objective on Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research report on Friday, June 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of Stryker in a research note on Friday, July 31st. Argus set a $370.00 target price on shares of Stryker in a research note on Thursday, July 9th. Finally, Sanford C. Bernstein set a $410.00 target price on Stryker in a research report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, Stryker has an average rating of “Moderate Buy” and an average price target of $386.28.

Get Our Latest Report on Stryker

About Stryker

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.